This product is for research use only, not for human use. We do not sell to patients.
| Size | Price | Stock |
|---|---|---|
| 250mg | $950 | Check With Us |
| 500mg | $1500 | Check With Us |
| 1g | $2250 | Check With Us |
: Cat #: V0056 CAS #: 1005342-46-0 Purity ≥ 98%
Description: LCL161 (LCL-161) is a novel and potent SMAC (second mitochondrial-derived activator of caspases) mimetic agent with potential anticancer activity, acting by potently binding to and inhibiting multiple IAP (inhibitor of apoptosis) proteins such as XIAP and c-IAP.
References: Maria Ahn, et al. Potent, Dual cIAP1/XIAP Antagonists Induce Apoptosis in a Melanoma Stem Cell Population.
Publications Citing InvivoChem Products
Product Promise
- Physicochemical and Storage Information
- Protocol
- Related Biological Data
- Stock Solution Preparation
- Quality Control Documentation
| Molecular Weight (MW) | 500.63 |
|---|---|
| Molecular Formula | C26H33FN4O3S |
| CAS No. | 1005342-46-0 |
| Storage | -20℃ for 3 years in powder formr |
| -80℃ for 2 years in solvent | |
| Solubility In Vitro | DMSO: Soluble in DMSO > 10 mMr |
| Water: <1 mg/mL (slightly soluble or insoluble)r | |
| Ethanol: 20 mg/mL warming (39.94 mM) | |
| SMILES Code | C[C@H](NC)C(N[C@@H](C1CCCCC1)C(N2[C@H](C3=NC(C(C4=CC=C(F)C=C4)=O)=CS3)CCC2)=O)=O |
| Synonyms | LCL161; LCL 161; LCL-161 |
| Protocol | In Vitro | LCL161 shows anti-proliferative effects and reduces cell viability significantly in Hep3B (IC50=10.23 μM) and PLC5 (IC50=19.19 μM) cells in a dose-dependent manner. LCL161 induces apoptosis significantly in both the sensitive cell lines in a dose-dependent manner. LCL161 significantly down regulates the expression of cIAP1, starting at very low concentrations. LCL161 at low concentrations inhibits cIAP1 starting at the concentration of 0.5 nM. |
|---|---|---|
| In Vivo | Tumor-bearing mice are treated with vehicle or LCL161 p.o. at a dose of 50 mg/kg/day, or SC-2001 p.o. at a dose of 10 mg/kg/day, 5 days a week, or in combination for the duration of the study. Tumor growth is significantly inhibited by co-treatment with SC2001 and LCL161 and tumor size in the co-treatment group is only one third of that of the control group at the end of the study. |
| Solvent volume to be added | Mass (the weight of a compound) | |||
|---|---|---|---|---|
| Mother liquor concentration | 1mg | 5mg | 10mg | 20mg |
| 1mM | 1.9975 mL | 9.9874 mL | 19.9748 mL | 39.9497 mL |
| 5mM | 0.3995 mL | 1.9975 mL | 3.9950 mL | 7.9899 mL |
| 10mM | 0.1997 mL | 0.9987 mL | 1.9975 mL | 3.9950 mL |
| 20mM | 0.0999 mL | 0.4994 mL | 0.9987 mL | 1.9975 mL |
This equation is commonly abbreviated as: C1 V1 = C2 V2
- (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
- (2) Be sure to add the solvent(s) in order.